Table 2 A collection of preclinical as well as clinical PARPis drugs
Targeted | Drug name | Target | Study Phase | Reference |
|---|---|---|---|---|
Pan-PARP | Olaparib (Lynparza) | PARP1, PARP2 | FDA approval (OC) | [68] |
Niraparib (ZL-2306) | PARP1, PARP2 | FDA approval (OC) | [69] | |
Rucaparib (PF-01367338) | PARP | FDA approval (OC) | [70] | |
Talazoparib (BMN-673) | PARP1, PARP2 | FDA approval (BC) | [71] | |
Veliparib (ABT-888) | PARP1, PARP2 | phase III (Squamous Non-Small Cell Lung Cancer) | NCT02106546 | |
2X-121 | TNK 1/2 | phase II (Advanced Ovarian Cancer) | NCT03878849 | |
CEP-9722 | PARP, TNK | phase I (Advanced Solid Tumors) | NCT04335604 | |
BGB-290 (Pamiparib) | PARP1, PARP2 | phase II (Advanced or Inoperable Gastric Cancer) | NCT03427814 | |
JPI-547 | PARP, TNK | phase I (Advanced Solid Tumors) | NCT04335604 | |
INO-1001 | PARP | phase I (Melanoma) | NCT00272415 | |
A-966492 | PARP1, PARP2 | Preclinical | [72] | |
PJ-34 HCI | PARP | Preclinical | [73] | |
UPF1069 | PARP1, PARP2 | Preclinical | [74] | |
RK-287107 | TNK 1/2 | Preclinical | [75] | |
IMP4297 | PARP1, PARP2 | phase I (Advanced Solid Tumors and Small Cell Lung Cancer) | NCT04434482 | |
E7449 | PARP1, PARP2 | Phase I/II (Advanced Solid Tumors/B-cell Malignancies) | NCT01618136 | |
NU1025 | PARP | Preclinical | [76] | |
AZD2461 | PARP1 | phase I (Refractory Solid Tumors) | NCT01247168 | |
NMS-03305293 | PARP1 | phase I (Selected Advanced/Metastatic Solid Tumors) | NCT04182516 | |
Fluzoparib (SHR3162) | PARP1 | phase II (Relapsed Ovarian Cancer) | NCT04517357 | |
3-aminobenzamide | PARP1 | Preclinical | [77] | |
AG-14361 | PARP1 | Preclinical | [78] | |
NMS-P118 | PARP1 | Preclinical | [79] | |
ME0328 | PARP3 | Preclinical | [80] | |
NA | IDX-1197 | NA | phase II (HRR Mutated Solid Tumors) | NCT04174716 |
E7016 | NA | phase I (Advanced Solid Tumors) | NCT01127178 |